T-cell-mediated immunity is an important determinant in protection against primary infection with
Coccidioidomycosis is a mycotic disease caused by the dimorphic fungus Coccidioides immitis. The disease is endemic in the semiarid areas of Texas, Arizona, New Mexico, and southern California. Primary infection is acquired by inhalation of mycelial-phase arthroconidia, which enter the alveoli and undergo a morphologic conversion into endosporulating spherules (35) . Coccidioidomycosis presents a diverse clinical spectrum, ranging from benign, self-limited pulmonary infection to a severe, progressive, and often lethal extrapulmonary dissemination. Investigations in humans and experimentally infected animals have shown strong T-cell reactivity to coccidioidal antigens in subjects with controlled infection, whereas T-cell responses are depressed or nondemonstrable in subjects with progressive, multifocal disease (4, 6, 12-15, 26, 27) . Recovery from primary asymptomatic or benign infection with C. immitis confers lifelong immunity to exogenous reinfection. The acquired resistance is associated with the acquisition of a delayed-type hypersensitivity response and the production of T helper-1 (Th1)-associated cytokines, such as gamma interferon (IFN-␥) and interleukin-2 (IL-2), to coccidioidal antigens (4, 6, 12-15, 26, 27) .
IL-12, a heterodimeric Th1-promoting cytokine consisting of two disulfide-bonded subunits of 35 and 40 kDa, has been shown to have potent immunotherapeutic effects against tumor cells and a wide range of microbial pathogens (7, 11, 16, 20, 28, 29, 40, 42, 43) . This cytokine has pleiotropic effects, including activation of macrophages, augmentation of the cytolytic activity of NK and T cells, and induction of the Th1-associated cytokines, notably IFN-␥ (38) . In a previous study, we showed that IL-12 plays a critical role in host defense against C. immitis (27) . Treatment of the highly susceptible BALB/c mouse strain with recombinant murine IL-12 (mIL-12) ameliorated the course of the disease and enhanced production of IFN-␥. Daily injections of 0.1 g of the recombinant cytokine were required, however, to achieve optimal therapeutic effects. Since gene therapy offers a means for constitutive production of a protein in vivo, we engineered a retroviral construct containing the cDNA encoding the p40 and p35 subunits of IL-12 as a single chain. Treatment of BALB/c mice with J774 macrophages that had been transduced with the single-chain IL-12 retroviral construct afforded a significant level of protection against lethal pulmonary challenge with C. immitis and was accompanied by increased production of IFN-␥.
TCGGGTGGCGGCGGATCTAGGGTCATTCCA and downstream CGCTCT AGATCTAGTCGACCAATG. A 35-cycle PCR was performed to amplify the p40 and p35 fragments by high-fidelity PCR (Boehringer, Mannheim, Germany) under the following conditions: 94°C for 5 min; 94°C for 1 min, 55°C for 1.5 min, and 68°C for 1.5 min; and 72°C for 7 min. The single-chain PCR-amplified fragment for mIL-12 was constructed by linkage of the p35 and p40 cDNA fragments with the upstream primer of p40 and the downstream primer of p35 in a second round of PCR (22) . The 1.66-kb PCR fragment of mIL-12 was directly cloned into PCR 2.1 vector (TA cloning kit; Invitrogen, San Diego, Calif.) and sequenced to confirm the nucleotide sequence of the adjacent subunit regions, linker, and the p40 and p35 coding regions. Thereafter, the single-chain cDNA of mIL-12 was ligated into the pLXSN vector (Clontech, Palo Alto, Calif.). The pLXSN/p40.L⌬p35 construct, hereafter referred to as pLXSN/mIL-12, contains the gene encoding neomycin resistance as a selectable marker. The immunopotentiating capacity of the pLXSN/mIL-12 construct was compared with that of the pLXSN vector alone.
Cell transfection. The pLXSN/mIL-12 construct was transduced into the amphotropic packaging cell line PA317 by calcium phosphate precipitation (Gibco). After a 72-h incubation, supernatants were collected from the transduced cells and assayed for IL-12 by using the p75 enzyme-linked immunosorbent assay (ELISA) procedures as described below. Transfectants were selected by culturing the cells for 2 weeks in complete DMEM containing G418 (Gibco) at a concentration of 800 g/ml. IL-12 viral particle-producing PA317 clones were identified by reverse transcription (RT)-PCR (for both neomycin resistance gene and IL-12 mRNAs) and by a p75 ELISA as described below. IL-12-producing PA317 clones were expanded in DMEM, and virus-containing supernatant was harvested and used to infect J774 macrophages.
Expression of bioactive IL-12 by transduced J774 cells. To test the ability of the pLXSN/mIL-12 constructs to induce the expression of mIL-12, total RNA was isolated from 5 ϫ 10 6 transduced J774 cells and assayed for IL-12 mRNA by RT-PCR. PCR amplification was performed with primer pairs for ␤-actin (Clontech), the neomycin resistance gene (41) , and IL-12 (p40⌬p35 as described above) mRNA transcripts. Expression of IL-12 at the protein level was determined by a sandwich ELISA devised specifically to detect IL-12 p75. The capture antibody was a hamster immunoglobulin G (IgG) anti-mIL-12 monoclonal antibody (Red-T; PharMingen, San Diego, Calif.), which reacts with mIL-12 p35 and the p75 heterodimer but not the p40 monomer. Captured IL-12 was detected by the addition of biotinylated rat IgG2a anti-mIL-12 p40 (clone C17.8). Recombinant mIL-12 (PharMingen) was used to prepare a standard curve.
The bioactivity of the secreted IL-12 was assayed by measuring its ability to induce IFN-␥ production by spleen cells from nonimmune mice. For these experiments, spleens were collected from normal BALB/c mice and gently teased into single-cell suspensions. The spleen cell suspension was treated with isotonic ammonium chloride to lyse erythrocytes and, after being washed by centrifugation, the splenocytes were resuspended in DMEM containing 10% fetal bovine serum. The cells were dispensed into wells on a microtiter plate at a concentration of 2 ϫ 10 6 mononuclear cells per well. The cell cultures were incubated in medium alone or in medium containing a 1:10 dilution of the supernatant from the IL-12-transduced J774 cells. After a 48-h incubation at 37°C under 5% CO 2 , supernatants were collected for assays of IFN-␥ protein by a two-site sandwich ELISA by using rat IgG1 anti-mouse IFN-␥ monoclonal antibodies from clones R4-6A2 for capture and biotinylated XMG1.2 for detection (PharMingen) as previously reported (19) . Recombinant mouse IFN-␥ (PharMingen) was used to establish a standard curve.
Infection of mice. The procedure for infecting mice via a pulmonary route has been detailed in an earlier report (13) . In brief, arthroconidia were harvested from 6-to 8-week-old mycelial-phase cultures of C. immitis Silveira (ATCC 28868). The arthroconidial suspension was passed over a nylon column to remove hyphal elements, and the cells were enumerated by hemacytometer counts. Pulmonary challenge was performed by intranasal instillation of 60 arthroconidia in 30 l of physiologic saline.
Gene therapy. J774 cells, transduced with pLXSN/mIL-12 or with pLXSN alone, were administered via an intraperitoneal (i.p.) route 6 h after pulmonary challenge and again on days 1, 4, and 7. Control mice were treated in the same manner with saline alone. Mice were sacrificed at day 12 after challenge, and the lungs, livers, and spleens were collected, weighed, and homogenized. Serial dilutions of the homogenates were plated on mycobiotic medium (Difco Laboratories, Detroit, Mich.) for enumeration of fungal CFU.
To assess the effect of IL-12 gene therapy on the Th1 response in vivo, mice treated with the pLXSN/mIL-12-transduced J774 cells, vector-transduced J774 cells, or saline alone were sacrificed at 12 days postinfection, and their serum, lungs, and spleens were collected for assays of IFN-␥. Prior to assay, the lungs were suspended in sterile saline, homogenized in sterile Whirl-Pak bags (American Scientific Products, Dallas, Tex.), and filtered through a 22-m-pore-size membrane. The filtered lung homogenates and the serum samples were maintained at Ϫ70°C until assayed by the ELISA described above. For assays of IFN-␥ production by spleen cells, splenocytes (2 ϫ 10 6 ) were incubated in tissue culture medium alone or medium containing concanavalin A (ConA, 2 g; Sigma Chemical Co., St. Louis, Mo.). Forty-eight hours later, the spleen cell supernatants were collected and assayed for IFN-␥ by ELISA.
Statistical analysis. The statistical significance of differential findings between experimental groups of animals was determined by the nonparametric MannWhitney rank sum test. Findings were regarded as significant if two-tailed P values were Ͻ0.05.
RESULTS
Expression of bioactive mIL-12 in transduced cells. Generation of the functionally active IL-12 heterodimer requires the expression of both the p40 and the p35 genes (21, 22, 32) . Although this can be achieved by simultaneously transfecting cells with two separate plasmids encoding the p40 and p35 genes, excessive p40 expression has been shown to lead to the inhibition of the bioactivities of IL-12 in mice (9, 17) . To avoid this potential problem, we generated a single-chain construct containing both the p40 and the p35 genes (32), connected by a 45-bp linker encoding 15 amino acids (22) , with the neomycin resistance gene as a selectable marker. This polycistronic construct is depicted in Fig. 1 . J774 cells were infected by coculture with viral particlecontaining supernatant from pLXSN/mIL-12-transduced PA317 cells or PA317 cells that had been transduced with the pLXSN vector alone. The transduced J774 cell clones were obtained after a 2-week selection with G418 and examined for expression of IL-12 at both the molecular and protein levels by RT-PCR and IL-12 ELISA, respectively. The results obtained by the RT-PCR assays are shown in Fig. 2 . J774 cells transduced with pLXSN/mIL-12 expressed mRNAs for both fulllength 1.66-kb IL-12 and the 0.68-kb neomycin resistance gene, while vector-transduced J774 cells expressed mRNA only for the neomycin resistance gene. IL-12 was also detected when the supernatants from transduced J774 cells were assayed by ELISA, with a mean level of 28,440 pg from 10 6 cells in 48 h (Fig. 3A) . The secreted IL-12 was bioactive, as evidenced by the induction of 3,300 pg of IFN-␥ in resting spleen cells (Fig.  3B) . These IL-12-transduced J774 cells have constitutively produced bioactive IL-12 for over 1 year and have retained their original morphology, growth pattern, and expression of the cell Twelve days after challenge, the mice were sacrificed and examined for fungal CFU. The results, depicted in Fig. 4 , established that mice treated with pLXSN/mIL-12-transduced J774 macrophages showed a significant decrease in the number of C. immitis CFU in the lungs compared to the vector (P Ͻ 0.001) and saline control groups (P Ͻ 0.001). Recipients of the IL-12-transduced J774 cells also showed significant reductions in the fungal load in their spleens (P Ͻ 0.0001) and livers (P Ͻ 0.001).
It is perhaps noteworthy that mice given pLXSN/mIL-12-transduced J774 cells, but not those receiving vector-transduced cells, showed marked splenomegaly, with a greaterthan-twofold increase in weight compared to spleens from mice treated with the vector-transduced J774 cells. This finding is consistent with a recent report by Kim et al. (21) that mice given an IL-12 cDNA expression vector showed a level of splenomegaly that was comparable to that observed in mice given recombinant IL-12.
In vivo induction of Th1 response in mice given IL-12 gene therapy. The preceding results established that retroviral vector-mediated IL-12 gene therapy effected a significant decrease in the fungal load in the lungs, livers, and spleens of mice. To determine if this protection was accompanied by induction of IFN-␥, mice treated with the IL-12-transduced J774 or nontransduced cells were sacrificed 12 days after challenge, and their sera and lung homogenates were assayed for IFN-␥. As shown in Table 1 , sera from mice treated with the pLXSN/ mIL-12-transduced J774 cells showed 1,580 pg of IFN-␥ per ml, whereas no IFN-␥ was detected in sera from mice treated with the vector-transduced J774 cells or saline. Likewise, the mean IFN-␥ level in lung homogenates from mice treated with the pLXSN/mIL-12-transduced J774 cells was 1,300 pg/100 mg of tissue, compared to 200 pg and Ͻ15 pg in lung tissue from mice treated with the pLXSN vector or saline alone, respectively. Further proof that the transduced J774 cells induced IFN-␥ production in vivo was evidenced by our finding that spleen cells from mice treated with the pLXSN/mIL-12-transduced J774 cells secreted 290 pg of IFN-␥ when cultured in vitro in medium alone (Table 2) . No IFN-␥ was detected when splenocytes from mice given saline alone or vector-transduced J774 cells were incubated in medium alone. When the spleen cells were assayed for IFN-␥ production in response to stimulation with ConA, cells from recipients of IL-12-transduced J774 cells secreted 3,900 pg compared to 60 and 160 pg by splenocytes from recipients of saline alone or vector-transduced J774 cells, respectively. The decreased production of IFN-␥ by ConA-stimulated spleen cells from the latter two groups of mice is consistent with the immunosuppressive effect of active coccidioidomycosis on Th1-associated responses (12, 13, 15, 26) .
DISCUSSION
The results of this investigation demonstrate the efficacy of IL-12 gene therapy with a genetically engineered single-chain IL-12 fusion construct created by linkage of the p35 and p40 genes with a (Gly 4 Ser) 3 polylinker. The monomeric nature of this single-chain IL-12 fusion protein ensures equimolar expression of each subunit, thereby avoiding the formation of p40 dimers which have been shown to antagonize the activity of IL-12 (9, 17) . The bioactivity and efficacy of gene therapy with this construct were examined by treating BALB/c mice, which are highly susceptible to C. immitis (13) , with J774 cells transduced with the single-chain IL-12 construct. Recipients of the IL-12-transduced J774 cells showed a reduced fungal load in their lungs, livers, and spleens after pulmonary challenge and an increased production of the Th1-associated cytokine IFN-␥.
It is now clearly established that IL-12 plays a pivotal role in orchestrating the immune response by amplifying cytokine networks involved in the induction of Th1 cells while suppressing Th2 responses (38) . In murine studies, recombinant IL-12 has been shown to prevent growth of a wide spectrum of tumors (7, 22, 29) and to augment host resistance to several pathogens, including Mycobacterium tuberculosis (11) , Listeria monocytogenes (40) , Toxoplasma gondii (20) , Leishmania major (28), Schistosoma mansoni (42) , Histoplasma capsulatum (43) , Cryptococcus neoformans (16) , and C. immitis (27) . The limitations of recombinant cytokine therapy include the need for daily administrations, often with significant systemic toxicity (27, 45) , and the inability to target the cytokine to a specific organ or tissue site. To address these limitations, investigators have focused on using gene transfer therapy for the in vivo production of bioactive IL-12. This approach has proved to be highly effective as evaluated in experimental tumor models (8, 9, 17, 21-23, 30, 36, 45) and infectious diseases (1, 10, 18, 37, 39, 44) and appears to be without toxicity.
We have previously reported that IL-12 has an essential role in host defense against C. immitis (27) . Administration of 0.1 g of recombinant IL-12 to susceptible BALB/c mice on the day before pulmonary challenge with C. immitis and then daily for 12 days afterward resulted in a significant reduction in the fungal load in the spleens and livers but not the lungs. Protection at the lung level was not achieved even with the administration of a 10-fold-higher dose of the recombinant protein.
These results and the finding that mice treated with the higher dose showed toxic manifestations, evidenced by ruffled fur, lethargy, and a marked reduction in total body weight by 8 days postinfection (27) , led us to examine the efficacy of IL-12 gene therapy. In this investigation, we used a single-chain IL-12 retroviral construct expressed in J774 cells to provide a potent and stable delivery system for bioactive IL-12. Treatment of BALB/c mice with the IL-12-expressing J774 cells effected a reduction in the fungal load in tissues and induced IFN-␥ production, as evidenced by increased levels of IFN-␥ in serum and lungs from treated mice 12 days after challenge with C. immitis. The induction of IFN-␥ is an important consequence of IL-12 gene therapy, since this cytokine has been shown to activate macrophages to an anticoccidioidal level, both in vitro and in vivo (5, 14) .
The protective effect of IL-12 gene therapy has in other models been shown to be attributable to the induction of the IFN-␥ by NK cells and T lymphocytes and to the subsequent development of Th1 responses (10, 11, 16, 36, 38-40, 42, 43) . (2, 3, 24, 31) . Cytokine gene therapy is a promising approach for inducing efficient immune responses against infectious diseases. We have demonstrated the feasibility of IL-12 gene therapy for the treatment of coccidioidomycosis by retrovirally-transduced J774 cells. To our knowledge, this study is the first to show that gene therapy with a single-chain IL-12 fusion construct will induce protective immunity and increase IFN-␥ production in a fungal disease. The results are extremely encouraging and indicate that IL-12 gene therapy has potential as adjunct therapy for coccidioidomycosis.
